Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aptamer I8
- Development stage
- Preclinical
- Lead developer
- Università degli Studi di Milano
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Aptamer I8 is a host-directed DNA aptamer developed by researchers at the University of Milan. It is designed to target intercellular adhesion molecule-1 (ICAM-1) on host airway epithelial cells, specifically masking the conserved domain involved in host-virus interactions. By blocking the binding of human rhinoviruses (HRVs) to ICAM-1, Aptamer I8 acts as an entry inhibitor to prevent viral replication and subsequent infection. It is being investigated for the prevention and treatment of HRV infections, particularly to prevent rhinovirus-driven acute exacerbations in patients with chronic obstructive pulmonary disease (COPD).
- Other names
- aptamer I8
02
Targets
ICAM1 (Intercellular Adhesion Molecule 1)
Beyond the preview
Go deeper on Aptamer I8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aptamer I8.